for people ages 18 years and up (full criteria)
at La Jolla, California and other locations
study started
estimated completion



The purpose of this study is to evaluate the safety and tumor-shrinking ability of experimental medication BMS-986156, when given by itself or in combination with nivolumab in patients with solid cancers that are advanced or cancers that have spread.

Official Title

A Phase 1/2a Dose Escalation and Cohort Expansion Study for Safety, Tolerability, and Efficacy of BMS-986156 Administered Alone and in Combination With Nivolumab (BMS-936558, Anti PD-1 Monoclonal Antibody) in Advanced Solid Tumors


Solid Tumors Nivolumab BMS-986156 BMS-986156: Dose Escalation BMS-986156 + nivolumab (nivo): Dose Escalation BMS-986156: Dose Expansion BMS-986156 + nivolumab (nivo): Dose Expansion


For people ages 18 years and up

For more information regarding BMS clinical trial participation, please visit

Inclusion Criteria:

  • For Dose Escalation:
  • Subjects with any previously treated advanced (metastatic or refractory) solid tumor
  • For Cohort Expansion:
  • Subjects must have a previously treated advanced solid tumor to be eligible
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Willing and able to provide pre-treatment and on-treatment fresh tumor biopsy
  • Women of child-bearing potential and men must use an acceptable method of contraception during treatment and for 23 weeks after treatment for women and 31 weeks for men

Exclusion Criteria:

  • Known central nervous system metastases or central nervous system as the only source of disease
  • Other concomitant malignancies (with some exceptions per protocol)
  • Active, known or suspected autoimmune disease
  • Uncontrolled or significant cardiovascular disease
  • History of active or chronic hepatitis (e.g. Hep B or C)
  • Impaired liver or bone marrow function
  • Major surgery less than 1 month before start of the study


  • UCSD Moores Cancer Center
    La Jolla California 92093-0698 United States
  • Providence Portland Medical Center
    Portland Oregon 97213 United States


in progress, not accepting new patients
Start Date
Completion Date
Bristol-Myers Squibb
BMS Clinical Trial Information
BMS Clinical Trial Patient Recruiting
Investigator Inquiry Form
FDA Safety Alerts and Recalls
Phase 1/2
Study Type
Last Updated